Featured Education

On Demand Activities

More results...

Therapeutics Areas
Learner Specialties
Expires After
  • On-Demand
The Burden of Vaccine-Preventable Disease: Assessing Risk in Older Adults
  • Credit: 0.50hr(s)
  • AAFP, AAPA, ABIM, CME, IPCE, MOC, NCPD, Royal College MOC 
  • June 28, 2024 — 
  • June 27, 2025
  • Therapeutic Areas: Family Medicine / Primary Care
  • Specialties: Primary Care
  • Location: Internet Activity Enduring
Healthcare providers (HCPs) encounter significant challenges in vaccine acceptance. A critical need exists among primary care providers (PCPs) to remain abreast of the continuously evolving vaccination landscape. As such, PCPs need to be able to evaluate the burden of vaccine-preventable diseases, provide well-founded recommendations for vaccine measures, and apply appropriate strategies to address vaccine hesitations.
Access Course
  • On-Demand
Dermatology Dialogues | Gaining and Maintaining Flare Control in Moderate-to-Severe Atopic Dermatitis: Enhancing Patient Quality of Life
  • Credit: 1.0hr(s)
  • AAPA, ABIM, CME, IPCE, MOC
  • December 22, 2023 — 
  • December 21, 2024
  • Therapeutic Areas: Allergy, Dermatology
  • Specialties: Atopic Dermatitis
  • Location: Internet Activity Enduring
This 4 part-15 minute segmented vodcast/podcast will unite dermatology and allergy clinicians, who provide care for patients with moderate-to-severe atopic dermatitis (M-S AD).
Access Course
  • On-Demand
Enhancing Patient Care for CAR T-Cell Therapy in NHL: Comprehensive Solutions for Your Community
  • Credit: 1.0hr(s)
  • ABIM, CME, IPCE, MOC, NCPD, Royal College MOC 
  • June 15, 2024 — 
  • June 14, 2025
  • Therapeutic Areas: Chronic Lympoblastic Leukemia (CLL)
  • Specialties: Mantle Cell Lymphoma
  • Location: Internet Activity Enduring
In this Build Your Own Case Study | Enhancing Patient Care for CAR T-Cell Therapy in NHL: Comprehensive Solutions for Your Community, learn from expert faculty about the most recent clinical updates and emerging real-world efficacy and safety data of CAR T-cell therapies in NHL. Build Your Own Case Study will guide participants through an interactive learning progression, as they go through two patient scenarios and make selections at critical decision points. Participants will be provided with patient clinical presentation and other relevant factors including age, time and aggressiveness of relapse, social history, genetic profiling/molecular testing results, cytogenetic risk factors, disease subtype, comorbidities, and prior therapies in order to make appropriate treatment decisions. Expert faculty will discuss participant selection of treatments, sequencing considerations, and drug-related toxicities. The activity will conclude with a discussion on how to develop strategies to assist patients with coordinated care and long-term disease management after the receipt of CAR T-cell therapy. This ancillary educational activity is derived from the 2024 ASCO Annual Meeting, originally held on May 31, 2024
Access Course
  • On-Demand
Taking a Team Approach: Community-based Practices at the Forefront of NHL and HL Care
  • Credit: 0.25hr(s)
  • AAPA, ABIM, CME, CPE, MOC, NCPD, Royal College MOC 
  • May 15, 2024 — 
  • May 14, 2025
  • Therapeutic Areas: Pan Tumor, Pathology, Pharmacy
  • Specialties: Pathology, Pharmacy
  • Location: Internet Activity Enduring
In this third episode, “Taking a Team Approach: Community-based Practices at the Forefront of NHL and HL Care,” from the 4-part series Med Table Talk, “The Power of the Community: Translating Innovations into Care in NHL and HL,” join expert faculty and special guest, Caitlin Murphy, DNP to discuss community-based practices for the treatment of NHL and HL. This episode will focus on how to best evaluate patients for and increase participation in clinical trials. Additional conversations will revolve around assessing patient quality of life, recognizing social determinants of health that impact patient care, and recognizing healthcare barriers and inequities in your own patient population. This episode will conclude with a conversation about misperceptions for CAR T-cell therapy and how to best coordinate care for patients receiving either CAR T-cell therapy or bispecific antibody therapy.
Access Course
  • On-Demand
Breathing Easy: Conquering Obstructive Sleep Apnea for Better Health - Screening and Management of OSA
  • Credit: 0.50hr(s)
  • AAFP, AAPA, CME, MOC
  • February 21, 2024 — 
  • February 20, 2025
  • Therapeutic Areas: Family Medicine / Primary Care
  • Location: Internet Activity Enduring
Obstructive Sleep Apnea (OSA) is a prevalent but often underestimated sleep disorder with significant implications for the health and well-being of individuals in the United States. Despite its impact on chronic diseases and healthcare costs, OSA remains underdiagnosed, leading to untreated sleep apnea and its consequences. With emerging strategies for OSA treatment, it’s crucial for healthcare providers to stay informed about the latest clinical evidence shaping the treatment landscape. Explore the 3-part on-demand series, Breathing Easy: Conquering Obstructive Sleep Apnea for Better Health. This collaborative effort, in conjunction with local AAFP Chapter meetings, provides expert guidance and clinical best practices for screening, managing, monitoring, and treating patients with OSA
Access Course
  • On-Demand
Bridging the Gap to Reach Treatment Goals in DLBCL
  • Credit: 1.0hr(s)
  • AAPA, CME, CPE, NCPD
  • March 15, 2023 — 
  • February 28, 2024
  • Therapeutic Areas: Hematologic Oncology, Hematology
  • Specialties: CAR T-Cell Therapy, Lymphoma
  • Location: Internet Activity Enduring
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, which typically occurs in patients over the age of 60 years. While chemoimmunotherapy (R-CHOP) has been considered the first line treatment option, approximately 40% of patient with DLBCL will fail to respond and experience a relapse. Autologous hematopoietic stem cell transplantation (AHCT) has been used as treatment for patients who experience a relapse; however, many patients are ineligible for the procedure due to age, comorbidities, or resistance to second-line chemoimmunotherapy. Novel treatment options have thus been introduced to the treatment landscape of DLBCL, including chimeric antigen receptor T-cell therapy (CAR T) with trial results displaying sustained remissions for relapsed patients. Because the options for treatment of DLBCL have changed rapidly, it is important for treating physicians to be aware of the options that are available as well as assist them in overcoming barriers that may impact their treatment. Join us for this educational Med Table Talk® LIVE on Bridging the Gap to Reach Treatment Goals in DLBCL as our experts have a candid conversation about the available treatment options for DLBCL, how cellular therapists and community physicians must communicate to ensure adequate care between referring and treating physicians, and how to recognize and address common treatment barriers. This taped satellite symposium was derived from the 2023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCTTM and CIBMTR® on February 18, 2023.
Access Course
View All MLI Activities
Facebook Twitter Linkedin Instagram
Subscribe to Mailing List
Scroll to Top